The prevalence of HPV-18 and variants of E6 gene isolated from cervical cancer patients in Taiwan

被引:11
作者
Chang, CH
Chen, TH
Hsu, RC
Chou, PH
Yang, JH
Hwang, GY
机构
[1] Tunghai Univ, Dept Life Sci, Taichung, Taiwan
[2] Changhua Christian Hosp, Dept Obstet & Gynecol, Changhua, Taiwan
[3] Chung Shan Med Univ, Sch Dent, Taichung, Taiwan
关键词
human papillomavirus type 18 (HPV-18); cervical cancer; variants;
D O I
10.1016/j.jcv.2004.06.011
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background : Cervical cancer is the second most common cancer in women worldwide. It has been considered that human papillomavirus (HPV) is associated with cervical cancer. Currently, more than 80 different serotypes of HPV have been characterized and they are divided into low- and high-risk groups. The most common types that lead to cervical cancer are HPV-16 and -18. The viral oncogenes E6 and E7 are associated with the development of cervical cancer. In previous study, the variants of HPV-16 E6 gene have been reported. It suggests that variants may influence the morbidity of carcinogenesis, but the variant study on HPV-18 remains unknown. Objectives : To identify the variants of integrated HPV-18 E6 gene in the prevalent infection of HPV-18 of cervical cancer patients. Study design : 25 cervical cancer patients were clinically identified and the biopsies were obtained. The infectious HPV types were identified by PCR and Southern blotting analysis. The DNA fragments of the integrated HPV-18 E6 were amplified by PCR and cloned. The nucleotide sequences were obtained by sequencing. Results : The prevalence of HPV infection in our 25 cases was HPV-18 (100%) and 7 out of these 25 cases (28%) were co-infected with HPV-16. The most dominant mutation among 25 tested patients was a silence mutation C183G of the E6 coding region. Conclusions: The prevalent HPV infectious serotype is HPV-18, which differs from the worldwide prevalent type. The identified HPV-18 E6 variants had a unique silence mutation located on C183G in E6 coding region. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:33 / 37
页数:5
相关论文
共 31 条
[1]   HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND E7 ANTIBODIES IN HUMAN SERA - INCREASED ANTI-E7 PREVALENCE IN CERVICAL-CANCER PATIENTS [J].
BLEUL, C ;
MULLER, M ;
FRANK, R ;
GAUSEPOHL, H ;
KOLDOVSKY, U ;
MGAYA, HN ;
LUANDE, J ;
PAWLITA, M ;
TERMEULEN, J ;
VISCIDI, R ;
GISSMANN, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 1991, 29 (08) :1579-1588
[2]   The causal relation between human papillomavirus and cervical cancer [J].
Bosch, FX ;
Lorincz, A ;
Muñoz, N ;
Meijer, CJLM ;
Shah, KV .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (04) :244-265
[3]   Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parameters [J].
Brady, CS ;
Duggan-Keen, MF ;
Davidson, JA ;
Varley, JM ;
Stern, PL .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :3233-3240
[4]   Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein [J].
Chan, HM ;
Smith, L ;
La Thangue, NB .
ONCOGENE, 2001, 20 (43) :6152-6163
[5]   The integration of HPV-18 DNA in cervical carcinoma [J].
Corden, SA ;
Sant-Cassia, LJ ;
Easton, AJ ;
Morris, AG .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1999, 52 (05) :275-282
[6]   Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population [J].
Cuschieri, KS ;
Cubie, HA ;
Whitley, MW ;
Seagar, AL ;
Arends, MJ ;
Moore, C ;
Gilkisson, G ;
McGoogan, E .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (01) :68-72
[7]   The regulation of E2F by pRB-family proteins [J].
Dyson, N .
GENES & DEVELOPMENT, 1998, 12 (15) :2245-2262
[8]   Ecological and immunological determinants of influenza evolution [J].
Ferguson, NM ;
Galvani, AP ;
Bush, RM .
NATURE, 2003, 422 (6930) :428-433
[9]   High prevalence of human papillomavirus type 58 in Mexican colposcopy patients [J].
González-Losa, MD ;
Rosado-Lopez, I ;
Valdez-González, N ;
Puerto-Solís, M .
JOURNAL OF CLINICAL VIROLOGY, 2004, 29 (03) :202-205
[10]  
Hu XR, 1999, INT J CANCER, V83, P34, DOI 10.1002/(SICI)1097-0215(19990924)83:1<34::AID-IJC7>3.3.CO